アルツハイマー病による認知症のアジテーションに関するIGC-AD1試験 (CALMA)
アルツハイマー病による認知症の参加者の動揺に対するIGC-AD1の安全性と有効性の第2相、多施設、二重盲検、無作為化、プラセボ対照試験
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from Alzheimer's.
調査の概要
詳細な説明
CALMA is a multi-center, double-blind, randomized, placebo-controlled clinical trial. The study targets participants aged 60 and older with mild to severe Alzheimer's dementia who have exhibited clinically significant agitation for at least two weeks prior to enrollment. Agitation caused by other conditions or transient symptoms must be ruled out. Eligibility is determined by a baseline Neuropsychiatric Inventory (NPI-12), Agitation subscale score of ≥4 and the International Psychogeriatric Association (IPA) criteria for agitation.
The investigational medication is an oral solution containing two active ingredients: delta-9 tetrahydrocannabinol (THC) and melatonin. The treatment is administered for 42 days, followed by a two-day taper period at the end of the study.
Safety oversight includes daily calls on days 2, 3, and 4, transitioning to calls every third day thereafter. These calls will review study partners logbook entries, changes in concomitant medications, and adverse events.
The primary objective of the study is to evaluate the efficacy of IGC-AD1 on agitation, measured by changes in the Cohen-Mansfield Agitation Inventory (CMAI) scores from baseline to the End of treatment (EOT). The secondary objective is to assess efficacy by examining CMAI score changes from baseline to week two. Additionally, exploratory objectives are outlined in separate documentation.
Blood samples will be collected during the trial for sparse pharmacokinetic (PK) analysis, blood-based CNS biomarker, and genotyping.
研究の種類
入学 (推定)
段階
- フェーズ2
連絡先と場所
研究場所
-
-
Florida
-
Maitland、Florida、アメリカ、32751
- ClinCloud, LLC
-
Melbourne、Florida、アメリカ、32940
- ClinCloud, LLC
-
Miami、Florida、アメリカ、33133
- Visionary Investigators Network
-
Miami、Florida、アメリカ、33137
- Miami Jewish Health
-
Miami、Florida、アメリカ、33125
- Central Miami Medical Institute
-
Port Charlotte、Florida、アメリカ、33952
- Neurostudies Inc.
-
Tampa、Florida、アメリカ、33613
- University of South Florida Department of Psychiatry and Behavioral Neurosciences
-
-
Louisiana
-
Metairie、Louisiana、アメリカ、70006
- Tandem Clinical Research GI, LLC
-
-
Maryland
-
Baltimore、Maryland、アメリカ、21237
- MedStar Franklin Square Medical Center Neurology
-
Clinton、Maryland、アメリカ、20735
- Medstar Southern Maryland Hospital Center
-
Olney、Maryland、アメリカ、20832
- Medstar Montgomery Medical Center
-
-
Missouri
-
St Louis、Missouri、アメリカ、63128
- Tekton Research LLC
-
-
New York
-
Amherst、New York、アメリカ、02459
- Dent Neurologic Institute
-
Brooklyn、New York、アメリカ、11229
- Integrative Clinical Trials, LLC
-
Syracuse、New York、アメリカ、13210
- Ichor Research
-
-
Oklahoma
-
Oklahoma City、Oklahoma、アメリカ、73112
- Lynn Health Science Institute (LHSI)
-
-
Rhode Island
-
Providence、Rhode Island、アメリカ、02906
- Butler Hospital, Brown University
-
-
Texas
-
Austin、Texas、アメリカ、78757
- Senior Adults Specialty Research
-
Dallas、Texas、アメリカ、75231
- Kerwin Medical Center
-
Dallas、Texas、アメリカ、75231
- Baylor Scott and White Research Institute
-
-
Virginia
-
Richmond、Virginia、アメリカ、23219
- Dominion Medical Associates, Inc.
-
-
-
-
British Columbia
-
Victoria、British Columbia、カナダ、V8R 1J8
- Island Health Authorities
-
-
Ontario
-
Hamilton、Ontario、カナダ、L8M 1W9
- Hamilton Health Sciences , Mcmaster University
-
Toronto、Ontario、カナダ、ON M6A 2E1
- Baycrest Academy for Research and Education , University of Toronto
-
-
Quebec
-
Montreal、Quebec、カナダ、H4H 1R3
- Douglas Hospital Research Center, McGill university
-
-
-
-
-
Bayamón、プエルトリコ、00961
- SCB Research Center Corp
-
Rio Piedras、プエルトリコ、00935
- The Alliance, Medical Sciences Campus University of Puerto Rico
-
-
Bayamón
-
Bayamón、Bayamón、プエルトリコ、00961
- Instituto Sanacoop
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
To be eligible to participate in this study, the participant must meet all the following criteria:
Inclusion Criteria
-
Participant and/or Caregiver must provide a signed and dated ICF prior to any study procedures.
-
Must have a Caregiver who is able and willing to comply with all required study procedures.
-
The Caregiver must be known to the Participant and must be able to use electronic devices such as a cell phone, video conference over a laptop or cell phone, weighing scale, and be able to learn to take blood pressure, among others.
-
Based on local practice, Participants that cannot consent may have Caregiver's consent provided the Caregiver has among others a) Power of Attorney, b) is a spouse, or c) a sibling or d) a child or e) a close relation. The practice of accepting consent must be consistent with established practice at the site and jurisdiction.
-
Participants must consent to CYP450 and apolipoprotein E (ApoE) genotyping, and pharmacokinetics.
-
Diagnosis of AD by NIA-AA criteria
-
Clinically significant Agitation assessed by:
- NPI (Agitation) ≥ 4
- The presence of clinically significant, persistent Agitation based on the IPA definition (Appendix C) rather than those with recent onset and occasional symptoms, and
- Agitation not attributable to another psychiatric disorder, suboptimal care conditions, other underlining medical condition, or the physiological effects of a substance.
-
Negative drug screen, except for benzodiazepines if Participant has been using them in stable doses for at least 3 months before screening.
-
All medications used for behavioral symptoms should be consistent for at least 6 weeks before screening, with allowance for dose changes up to 25%.
-
Women must be of no childbearing potential (postmenopausal, defined as cessation of menses for at least 12 months, without an alternative medical cause for amenorrhea) or surgically sterile (hysterectomy, bilateral oophorectomy, or bilateral tubal ligation)).
An individual who meets any of the following criteria will be excluded from participation in this study:
Exclusion Criteria
- Prior adverse reaction to cannabinoids or to any component of Study Drug (IGC-AD1 and placebo).
- Serious or unstable medical illness, including cardiovascular, hepatic, renal, respiratory, endocrine, neurologic, or hematologic disease, which might confound assessment of safety outcomes.
- History of seizures, schizophrenia, or bipolar disorder.
- Has participated in an investigational drug or device study within 30 days prior to study start.
- Urine drug screen positive for drug use, except for benzodiazepines if Participant was using them previously and their dose had remained stable for at least six weeks before screening.
- History of Alcohol and Drug use disorder, within one year prior to enrollment.
- Hypertension: Participants with a history of uncontrolled hypertension as determined by the PI and Participants with a hypertensive crisis in the six months prior to enrollment.
- Falls: Participants with a history of recurrent falls defined as more than two falls in the six-month period prior to enrollment and a history of falls resulting in injuries or associated with a new acute illness, loss of consciousness, fever, or abnormal blood pressure (Fuller et al., 2000).
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:ランダム化
- 介入モデル:並列代入
- マスキング:トリプル
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
アクティブコンパレータ:Active Comparator: IGC-AD1Active
IGC-AD1-Active, oral solution with two APIs (THC and melatonin). |
A non-sterile solution for oral administration.
他の名前:
|
|
プラセボコンパレーター:Placebo Comparator: IGC-AD1 Placebo
IGC-AD1-Placebo, oral solution similar to Active in color, taste, and texture, with excipients but without APIs. |
A non-sterile solution for oral administration similar in color and texture to the Active.
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Agitation
時間枠:Baseline to week six
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week six
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Acute Agitation
時間枠:Baseline to week two
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week two
|
その他の成果指標
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Agitation at week four
時間枠:Baseline to week four
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score |
Baseline to week four
|
|
Participant overall wellbeing
時間枠:Baseline to weeks two and six
|
Change in the Clinical Global Impression Scale (CGI) |
Baseline to weeks two and six
|
|
Participant executive functions
時間枠:Baseline to week six
|
Change in Mini-Mental State Examination (MMSE2) score |
Baseline to week six
|
|
Depression
時間枠:Baseline to weeks two, four, and six
|
Change in mean Cornell Scale for Depression in Dementia (CSDD) score |
Baseline to weeks two, four, and six
|
|
Neuropsychiatric symptoms
時間枠:Baseline to weeks two, four, and six
|
Change in mean Neuropsychiatric Inventory (NPI-12) score |
Baseline to weeks two, four, and six
|
|
Participant quality of life
時間枠:Baseline to weeks two, four and six
|
Change in mean Quality of Life in Alzheimer's Disease (QOL-AD) score |
Baseline to weeks two, four and six
|
|
Caregiver burden
時間枠:Baseline to weeks two and six
|
Change in mean Zarit Burden Interview (ZBI) score |
Baseline to weeks two and six
|
|
Psychotropic drugs
時間枠:Baseline to six weeks
|
Change in type and dosage of psychotropic drugs |
Baseline to six weeks
|
|
CYP2C9 polymorphisms on agitation
時間枠:Baseline to weeks two, four and six
|
Change in mean Cohen Mansfield Agitation Inventory (CMAI) score for each type of metabolizer group (*1/*1, *1/*3, etc.) |
Baseline to weeks two, four and six
|
協力者と研究者
スポンサー
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IGC-AD1-P2 BIDAG
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。